Wasatch Advisors LP Boosts Stake in Immatics (NASDAQ:IMTX)

Wasatch Advisors LP grew its stake in Immatics (NASDAQ:IMTX) by 9.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 957,052 shares of the company’s stock after acquiring an additional 84,541 shares during the quarter. Wasatch Advisors LP’s holdings in Immatics were worth $6,805,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in the stock. Guggenheim Capital LLC bought a new stake in Immatics during the fourth quarter valued at about $101,000. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in shares of Immatics by 24.6% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 22,701 shares of the company’s stock valued at $163,000 after buying an additional 4,477 shares during the last quarter. Aristides Capital LLC bought a new stake in shares of Immatics in the 4th quarter valued at about $205,000. Y Intercept Hong Kong Ltd purchased a new position in shares of Immatics in the 4th quarter worth approximately $211,000. Finally, State Street Corp grew its position in shares of Immatics by 11.2% in the 3rd quarter. State Street Corp now owns 225,202 shares of the company’s stock worth $2,570,000 after buying an additional 22,710 shares during the last quarter. 64.41% of the stock is owned by institutional investors.

Immatics Stock Down 5.9 %

Shares of Immatics stock opened at $4.11 on Thursday. The company has a 50 day moving average price of $4.51 and a 200 day moving average price of $6.68. The firm has a market capitalization of $499.57 million, a P/E ratio of -6.23 and a beta of 0.85. Immatics has a 52 week low of $3.30 and a 52 week high of $13.77.

Immatics (NASDAQ:IMTX) last posted its quarterly earnings results on Thursday, March 27th. The company reported $0.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.51. The business had revenue of $15.67 million during the quarter, compared to analysts’ expectations of $16.16 million. Immatics had a negative net margin of 47.94% and a negative return on equity of 15.90%. As a group, research analysts anticipate that Immatics will post -0.72 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Cantor Fitzgerald restated an “overweight” rating on shares of Immatics in a research note on Tuesday, April 1st. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Immatics currently has an average rating of “Buy” and an average price target of $16.67.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.